Discover
GANX
Gain Therapeutics, Inc.
1.84
2 x 1.75
1 x 1.85
bid
ask
+
0.21
12.88%
2 @ 04:00 PM
1.86 +0.02 (1.20%)
| Ytd | -42.86% | |
| 1y | 16.46% |
1.63
day range
1.85
1.41
52 week range
4.34
| Open | 1.65 | Prev Close | 1.63 | Low | 1.63 | High | 1.85 | Mkt Cap | 78.48M |
| Vol | 682.76K | Avg Vol | 882.65K | EPS | -0.58 | P/E | -3.17 | Forward P/E | -1.76 |
| Beta | 0.15 | Short Ratio | 1.65 | Inst. Own | 7.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.78 | 200-d Avg | 2.20 | 1yr Est | 7.33 |
GANX News
benzinga.com
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Opera
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued signif
globenewswire.com
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or
benzinga.com
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) wit
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
benzinga.com
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S.,
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session